Drug Profile
Interleukin-2 gene therapy - Valentis
Alternative Names: IL-2 genemedicine; Interleukin-2 genemedicine; VLTS-587Latest Information Update: 25 Jan 2017
Price :
$50
*
At a glance
- Originator Valentis
- Class Antineoplastics; Cytokine genes; Gene therapies; Interleukins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Head and neck cancer; Lung cancer; Malignant melanoma
Most Recent Events
- 24 Jan 2017 Discontinued - Phase-I for Lung cancer in USA (IV)
- 24 Jan 2017 Discontinued - Phase-II for Head and neck cancer in Russia, Germany, Czech Republic (Intratumoural)
- 24 Jan 2017 Discontinued - Phase-II for Malignant melanoma in USA (Intratumoural)